Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
Subscribe To Our Newsletter & Stay Updated
